To include your compound in the COVID-19 Resource Center, submit it here.

EC approves Roche's Gazyvaro to treat follicular lymphoma

Roche (SIX:ROG; OTCQX:RHHBY) said the European Commission approved Gazyvaro obinutuzumab (RG7159, GA101, RO5072759) to

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE